查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1876005

脂質體阿黴素：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Liposomal Doxorubicin - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 108 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球脂質體阿黴素市場規模預計為 9.74 億美元，預計到 2031 年將下降至 7.24 億美元，在 2025 年至 2031 年的預測期內，複合年成長率為 -3.5%。

本報告對近期關稅調整和國際對脂質體阿黴素採取的戰略反制措施的跨境產業佈局、資本配置模式、區域經濟相互依存關係以及供應鏈重組進行了全面評估。

脂質體阿黴素是一種化療藥物，其主要成分阿黴素（蔥環類抗生素）被包裹在脂質體（微小的球形脂質囊泡）中。這種脂質體製劑能夠增強藥物向腫瘤組織的遞送，延長藥物在血液中的循環時間，並降低心臟毒性和其他與傳統阿黴素相關的全身性副作用。它可用於治療多種癌症，包括卵巢癌、乳癌、多發性骨髓瘤和卡波西氏肉瘤，特別適用於對標準化療副作用敏感的患者。

脂質體阿黴素市場的主要促進因素是人們對更安全、更有效的癌症治療方法的需求日益成長，這些方案需要在保持療效的同時最大限度地降低全身毒性。傳統阿黴素廣泛應用於腫瘤治療，但它會帶來嚴重的副作用，尤其是劑量限制性心臟毒性。脂質體製劑透過將阿黴素包裹在脂質雙層中來解決這一難題，從而實現藥物靶向遞送至腫瘤部位，同時減少對正常組織的暴露。這顯著提高了藥物的安全性和患者耐受性，尤其是在長期或合併化療中。人口老化、生活方式改變和診斷能力的提高導致全球癌症負擔日益加重，進而引發了對先進腫瘤治療方案的激增，進一步推動了脂質體製劑的應用。此外，隨著個人化醫療和標靶藥物遞送系統的日益普及，脂質體阿黴素因其與脂質體製劑技術的兼容性，正逐漸成為轉移性乳癌、卵巢癌、多發性骨髓瘤和卡波西氏肉瘤等疾病的首選治療方案。監管機構的核准以及支持其作為一線治療和挽救治療療效的臨床證據，也促進了其市場認知度和應用範圍的不斷擴大。

儘管脂質體阿黴素具有治療優勢，但其市場仍面臨許多顯著挑戰。其中一個主要障礙是脂質體製劑高的研發和生產成本。為確保其穩定性、生物利用度和批間一致性，需要複雜的生產流程和嚴格的品管。因此，其價格遠高於傳統化療，這可能會限制患者的用藥，尤其是在中低收入國家和醫療預算緊張的地區。此外，部分市場非專利藥脂質體阿黴素的上市加劇了價格壓力和競爭，引發了人們對原廠藥（如Doxil（歐洲名稱：Kalix））市場佔有率和利潤率的擔憂。供應鏈問題和以往脂質體阿黴素的供不應求影響了患者的治療依從性，並削弱了人們對產品供應的信心。此外，脂質體製劑的生物等效性和產品替代方面的監管複雜性也為非專利處方藥的市場准入和核准帶來了挑戰。從臨床角度來看，雖然脂質體阿黴素可以降低心臟毒性，但它也會引起其他不良反應，例如掌蹠紅斑感覺異常，這可能會影響患者的依從性。應對這些挑戰需要製劑創新、經濟高效的生產、監管協調以及對真實世界療效數據的持續投入，以支持脂質體化療藥物的更廣泛應用。

本報告旨在按地區/國家、類型和應用對全球脂質體阿黴素市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以銷售（千）和收入（百萬美元）為單位，對脂質體阿黴素市場規模、估算和預測進行了呈現，基準年為2024年，並涵蓋了2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定脂質體阿黴素的業務/成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Johnson & Johnson
  • Sun Pharmaceutical
  • CSPC
  • Kinyond
  • Teva
  • Fudan-Zhangjiang
  • Zydus Cadila
  • TTY Biopharma
  • Baxter International
  • Nippon Kayaku

按類型分類的細分市場

  • 5 ml
  • 10 ml
  • 25 ml

應用領域

  • 乳癌
  • 肝癌
  • 腎癌
  • 多發性骨髓瘤
  • 卵巢癌
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Liposomal Doxorubicin was estimated to be worth US$ 974 million in 2024 and is forecast to a readjusted size of US$ 724 million by 2031 with a CAGR of -3.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Liposomal Doxorubicin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Liposomal doxorubicin is a chemotherapeutic drug in which doxorubicin, a widely used anthracycline antibiotic for cancer treatment, is encapsulated within liposomes-tiny, spherical lipid-based vesicles. This liposomal formulation enhances the drug's delivery to tumor tissues, prolongs circulation time in the bloodstream, and reduces cardiotoxicity and other systemic side effects commonly associated with conventional doxorubicin. It is used to treat various cancers, including ovarian cancer, breast cancer, multiple myeloma, and Kaposi's sarcoma, particularly in patients who are sensitive to the adverse effects of standard chemotherapy.

A key driver of the liposomal doxorubicin market is the increasing demand for safer and more effective cancer therapies that minimize systemic toxicity while maintaining therapeutic efficacy. Traditional doxorubicin, though widely used in oncology, is associated with severe adverse effects, particularly dose-limiting cardiotoxicity. The liposomal formulation addresses this issue by encapsulating doxorubicin in lipid bilayers, enabling targeted delivery to tumor sites while reducing exposure to healthy tissues. This significantly enhances the drug's safety profile and patient tolerability, especially in long-term or combination chemotherapy regimens. The growing global burden of cancer-driven by aging populations, lifestyle changes, and better diagnostic capabilities-has led to a surge in demand for advanced oncologic treatments, further propelling the use of liposomal formulations. Additionally, the increasing adoption of personalized medicine and targeted drug delivery systems aligns well with liposomal drug technologies, positioning liposomal doxorubicin as a preferred choice in indications such as metastatic breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma. Regulatory approvals and clinical evidence supporting its efficacy in both first-line and salvage therapy settings are also contributing to broader market acceptance and use.

Despite its therapeutic advantages, the liposomal doxorubicin market faces several notable challenges. One of the primary hurdles is the high cost of liposomal drug development and production, which involves complex manufacturing processes and strict quality controls to ensure stability, bioavailability, and batch consistency. This results in a significantly higher price point compared to conventional chemotherapy, which can limit accessibility-particularly in low- and middle-income countries or healthcare systems with constrained budgets. Moreover, the availability of generic liposomal doxorubicin products in some markets has led to pricing pressure and increased competition, raising concerns over market share and profit margins for originator brands like Doxil (Caelyx in Europe). Supply chain issues and past shortages of liposomal doxorubicin have also disrupted treatment continuity for patients and eroded confidence in product availability. Additionally, regulatory complexities related to bioequivalence and product substitution of liposomal formulations pose challenges for market entry and approval of generics. From a clinical perspective, while liposomal doxorubicin reduces cardiotoxicity, it may introduce other adverse effects such as palmar-plantar erythrodysesthesia (hand-foot syndrome), which can impact patient compliance. Addressing these challenges will require continued investment in formulation innovation, cost-effective manufacturing, regulatory harmonization, and real-world outcome data to support the broader adoption of liposomal chemotherapeutics.

This report aims to provide a comprehensive presentation of the global market for Liposomal Doxorubicin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Liposomal Doxorubicin by region & country, by Type, and by Application.

The Liposomal Doxorubicin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal Doxorubicin.

Market Segmentation

By Company

  • Johnson & Johnson
  • Sun Pharmaceutical
  • CSPC
  • Kinyond
  • Teva
  • Fudan-Zhangjiang
  • Zydus Cadila
  • TTY Biopharma
  • Baxter International
  • Nippon Kayaku

Segment by Type

  • 5 ml
  • 10 ml
  • 25 ml

Segment by Application

  • Breast Cancer
  • Liver Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Liposomal Doxorubicin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Liposomal Doxorubicin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Liposomal Doxorubicin in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Liposomal Doxorubicin Product Introduction
  • 1.2 Global Liposomal Doxorubicin Market Size Forecast
    • 1.2.1 Global Liposomal Doxorubicin Sales Value (2020-2031)
    • 1.2.2 Global Liposomal Doxorubicin Sales Volume (2020-2031)
    • 1.2.3 Global Liposomal Doxorubicin Sales Price (2020-2031)
  • 1.3 Liposomal Doxorubicin Market Trends & Drivers
    • 1.3.1 Liposomal Doxorubicin Industry Trends
    • 1.3.2 Liposomal Doxorubicin Market Drivers & Opportunity
    • 1.3.3 Liposomal Doxorubicin Market Challenges
    • 1.3.4 Liposomal Doxorubicin Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Liposomal Doxorubicin Players Revenue Ranking (2024)
  • 2.2 Global Liposomal Doxorubicin Revenue by Company (2020-2025)
  • 2.3 Global Liposomal Doxorubicin Players Sales Volume Ranking (2024)
  • 2.4 Global Liposomal Doxorubicin Sales Volume by Company Players (2020-2025)
  • 2.5 Global Liposomal Doxorubicin Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Liposomal Doxorubicin Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Liposomal Doxorubicin Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Liposomal Doxorubicin
  • 2.9 Liposomal Doxorubicin Market Competitive Analysis
    • 2.9.1 Liposomal Doxorubicin Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Liposomal Doxorubicin Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 5 ml
    • 3.1.2 10 ml
    • 3.1.3 25 ml
  • 3.2 Global Liposomal Doxorubicin Sales Value by Type
    • 3.2.1 Global Liposomal Doxorubicin Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Liposomal Doxorubicin Sales Value, by Type (2020-2031)
    • 3.2.3 Global Liposomal Doxorubicin Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Liposomal Doxorubicin Sales Volume by Type
    • 3.3.1 Global Liposomal Doxorubicin Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Liposomal Doxorubicin Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Liposomal Doxorubicin Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Liposomal Doxorubicin Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Breast Cancer
    • 4.1.2 Liver Cancer
    • 4.1.3 Kidney Cancer
    • 4.1.4 Multiple Myeloma
    • 4.1.5 Ovarian Cancer
    • 4.1.6 Other
  • 4.2 Global Liposomal Doxorubicin Sales Value by Application
    • 4.2.1 Global Liposomal Doxorubicin Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Liposomal Doxorubicin Sales Value, by Application (2020-2031)
    • 4.2.3 Global Liposomal Doxorubicin Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Liposomal Doxorubicin Sales Volume by Application
    • 4.3.1 Global Liposomal Doxorubicin Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Liposomal Doxorubicin Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Liposomal Doxorubicin Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Liposomal Doxorubicin Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Liposomal Doxorubicin Sales Value by Region
    • 5.1.1 Global Liposomal Doxorubicin Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Liposomal Doxorubicin Sales Value by Region (2020-2025)
    • 5.1.3 Global Liposomal Doxorubicin Sales Value by Region (2026-2031)
    • 5.1.4 Global Liposomal Doxorubicin Sales Value by Region (%), (2020-2031)
  • 5.2 Global Liposomal Doxorubicin Sales Volume by Region
    • 5.2.1 Global Liposomal Doxorubicin Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Liposomal Doxorubicin Sales Volume by Region (2020-2025)
    • 5.2.3 Global Liposomal Doxorubicin Sales Volume by Region (2026-2031)
    • 5.2.4 Global Liposomal Doxorubicin Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Liposomal Doxorubicin Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.4.2 North America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.5.2 Europe Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Liposomal Doxorubicin Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.7.2 South America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Liposomal Doxorubicin Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Liposomal Doxorubicin Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Liposomal Doxorubicin Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Liposomal Doxorubicin Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.3.2 United States Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.4.2 Europe Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.5.2 China Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.6.2 Japan Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.7.2 South Korea Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Liposomal Doxorubicin Sales Value, 2020-2031
    • 6.9.2 India Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Johnson & Johnson
    • 7.1.1 Johnson & Johnson Company Information
    • 7.1.2 Johnson & Johnson Introduction and Business Overview
    • 7.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Johnson & Johnson Liposomal Doxorubicin Product Offerings
    • 7.1.5 Johnson & Johnson Recent Development
  • 7.2 Sun Pharmaceutical
    • 7.2.1 Sun Pharmaceutical Company Information
    • 7.2.2 Sun Pharmaceutical Introduction and Business Overview
    • 7.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Sun Pharmaceutical Liposomal Doxorubicin Product Offerings
    • 7.2.5 Sun Pharmaceutical Recent Development
  • 7.3 CSPC
    • 7.3.1 CSPC Company Information
    • 7.3.2 CSPC Introduction and Business Overview
    • 7.3.3 CSPC Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 CSPC Liposomal Doxorubicin Product Offerings
    • 7.3.5 CSPC Recent Development
  • 7.4 Kinyond
    • 7.4.1 Kinyond Company Information
    • 7.4.2 Kinyond Introduction and Business Overview
    • 7.4.3 Kinyond Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Kinyond Liposomal Doxorubicin Product Offerings
    • 7.4.5 Kinyond Recent Development
  • 7.5 Teva
    • 7.5.1 Teva Company Information
    • 7.5.2 Teva Introduction and Business Overview
    • 7.5.3 Teva Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Teva Liposomal Doxorubicin Product Offerings
    • 7.5.5 Teva Recent Development
  • 7.6 Fudan-Zhangjiang
    • 7.6.1 Fudan-Zhangjiang Company Information
    • 7.6.2 Fudan-Zhangjiang Introduction and Business Overview
    • 7.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Product Offerings
    • 7.6.5 Fudan-Zhangjiang Recent Development
  • 7.7 Zydus Cadila
    • 7.7.1 Zydus Cadila Company Information
    • 7.7.2 Zydus Cadila Introduction and Business Overview
    • 7.7.3 Zydus Cadila Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Zydus Cadila Liposomal Doxorubicin Product Offerings
    • 7.7.5 Zydus Cadila Recent Development
  • 7.8 TTY Biopharma
    • 7.8.1 TTY Biopharma Company Information
    • 7.8.2 TTY Biopharma Introduction and Business Overview
    • 7.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 TTY Biopharma Liposomal Doxorubicin Product Offerings
    • 7.8.5 TTY Biopharma Recent Development
  • 7.9 Baxter International
    • 7.9.1 Baxter International Company Information
    • 7.9.2 Baxter International Introduction and Business Overview
    • 7.9.3 Baxter International Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Baxter International Liposomal Doxorubicin Product Offerings
    • 7.9.5 Baxter International Recent Development
  • 7.10 Nippon Kayaku
    • 7.10.1 Nippon Kayaku Company Information
    • 7.10.2 Nippon Kayaku Introduction and Business Overview
    • 7.10.3 Nippon Kayaku Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Nippon Kayaku Liposomal Doxorubicin Product Offerings
    • 7.10.5 Nippon Kayaku Recent Development

8 Industry Chain Analysis

  • 8.1 Liposomal Doxorubicin Industrial Chain
  • 8.2 Liposomal Doxorubicin Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Liposomal Doxorubicin Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Liposomal Doxorubicin Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Liposomal Doxorubicin Market Trends
  • Table 2. Liposomal Doxorubicin Market Drivers & Opportunity
  • Table 3. Liposomal Doxorubicin Market Challenges
  • Table 4. Liposomal Doxorubicin Market Restraints
  • Table 5. Global Liposomal Doxorubicin Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Liposomal Doxorubicin Revenue Market Share by Company (2020-2025)
  • Table 7. Global Liposomal Doxorubicin Sales Volume by Company (2020-2025) & (K Unit)
  • Table 8. Global Liposomal Doxorubicin Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Liposomal Doxorubicin Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Liposomal Doxorubicin Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Liposomal Doxorubicin Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Liposomal Doxorubicin
  • Table 13. Global Liposomal Doxorubicin Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Liposomal Doxorubicin Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Liposomal Doxorubicin Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Liposomal Doxorubicin Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Liposomal Doxorubicin Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Liposomal Doxorubicin Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Liposomal Doxorubicin Sales Volume by Type: 2020 VS 2024 VS 2031 (K Unit)
  • Table 22. Global Liposomal Doxorubicin Sales Volume by Type (2020-2025) & (K Unit)
  • Table 23. Global Liposomal Doxorubicin Sales Volume by Type (2026-2031) & (K Unit)
  • Table 24. Global Liposomal Doxorubicin Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Liposomal Doxorubicin Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Liposomal Doxorubicin Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Liposomal Doxorubicin Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Liposomal Doxorubicin Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Liposomal Doxorubicin Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Liposomal Doxorubicin Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Liposomal Doxorubicin Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Liposomal Doxorubicin Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Liposomal Doxorubicin Sales Volume by Application: 2020 VS 2024 VS 2031 (K Unit)
  • Table 34. Global Liposomal Doxorubicin Sales Volume by Application (2020-2025) & (K Unit)
  • Table 35. Global Liposomal Doxorubicin Sales Volume by Application (2026-2031) & (K Unit)
  • Table 36. Global Liposomal Doxorubicin Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Liposomal Doxorubicin Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Liposomal Doxorubicin Price by Application (2020-2025) & (USD/Unit)
  • Table 39. Global Liposomal Doxorubicin Price by Application (2026-2031) & (USD/Unit)
  • Table 40. Global Liposomal Doxorubicin Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Liposomal Doxorubicin Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Liposomal Doxorubicin Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Liposomal Doxorubicin Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Liposomal Doxorubicin Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Liposomal Doxorubicin Sales Volume by Region (K Unit): 2020 VS 2024 VS 2031
  • Table 46. Global Liposomal Doxorubicin Sales Volume by Region (2020-2025) & (K Unit)
  • Table 47. Global Liposomal Doxorubicin Sales Volume by Region (2026-2031) & (K Unit)
  • Table 48. Global Liposomal Doxorubicin Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Liposomal Doxorubicin Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Liposomal Doxorubicin Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Liposomal Doxorubicin Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Liposomal Doxorubicin Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Liposomal Doxorubicin Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Liposomal Doxorubicin Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Liposomal Doxorubicin Sales Volume, (2020-2025) & (K Unit)
  • Table 56. Key Countries/Regions Liposomal Doxorubicin Sales Volume, (2026-2031) & (K Unit)
  • Table 57. Johnson & Johnson Company Information
  • Table 58. Johnson & Johnson Introduction and Business Overview
  • Table 59. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Johnson & Johnson Liposomal Doxorubicin Product Offerings
  • Table 61. Johnson & Johnson Recent Development
  • Table 62. Sun Pharmaceutical Company Information
  • Table 63. Sun Pharmaceutical Introduction and Business Overview
  • Table 64. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. Sun Pharmaceutical Liposomal Doxorubicin Product Offerings
  • Table 66. Sun Pharmaceutical Recent Development
  • Table 67. CSPC Company Information
  • Table 68. CSPC Introduction and Business Overview
  • Table 69. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. CSPC Liposomal Doxorubicin Product Offerings
  • Table 71. CSPC Recent Development
  • Table 72. Kinyond Company Information
  • Table 73. Kinyond Introduction and Business Overview
  • Table 74. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. Kinyond Liposomal Doxorubicin Product Offerings
  • Table 76. Kinyond Recent Development
  • Table 77. Teva Company Information
  • Table 78. Teva Introduction and Business Overview
  • Table 79. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. Teva Liposomal Doxorubicin Product Offerings
  • Table 81. Teva Recent Development
  • Table 82. Fudan-Zhangjiang Company Information
  • Table 83. Fudan-Zhangjiang Introduction and Business Overview
  • Table 84. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Fudan-Zhangjiang Liposomal Doxorubicin Product Offerings
  • Table 86. Fudan-Zhangjiang Recent Development
  • Table 87. Zydus Cadila Company Information
  • Table 88. Zydus Cadila Introduction and Business Overview
  • Table 89. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Zydus Cadila Liposomal Doxorubicin Product Offerings
  • Table 91. Zydus Cadila Recent Development
  • Table 92. TTY Biopharma Company Information
  • Table 93. TTY Biopharma Introduction and Business Overview
  • Table 94. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. TTY Biopharma Liposomal Doxorubicin Product Offerings
  • Table 96. TTY Biopharma Recent Development
  • Table 97. Baxter International Company Information
  • Table 98. Baxter International Introduction and Business Overview
  • Table 99. Baxter International Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 100. Baxter International Liposomal Doxorubicin Product Offerings
  • Table 101. Baxter International Recent Development
  • Table 102. Nippon Kayaku Company Information
  • Table 103. Nippon Kayaku Introduction and Business Overview
  • Table 104. Nippon Kayaku Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 105. Nippon Kayaku Liposomal Doxorubicin Product Offerings
  • Table 106. Nippon Kayaku Recent Development
  • Table 107. Key Raw Materials Lists
  • Table 108. Raw Materials Key Suppliers Lists
  • Table 109. Liposomal Doxorubicin Downstream Customers
  • Table 110. Liposomal Doxorubicin Distributors List
  • Table 111. Research Programs/Design for This Report
  • Table 112. Key Data Information from Secondary Sources
  • Table 113. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Liposomal Doxorubicin Product Picture
  • Figure 2. Global Liposomal Doxorubicin Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Liposomal Doxorubicin Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Liposomal Doxorubicin Sales Volume (2020-2031) & (K Unit)
  • Figure 5. Global Liposomal Doxorubicin Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Liposomal Doxorubicin Report Years Considered
  • Figure 7. Global Liposomal Doxorubicin Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Liposomal Doxorubicin Players Sales Volume Ranking (2024) & (K Unit)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Liposomal Doxorubicin Revenue in 2024
  • Figure 10. Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. 5 ml Picture
  • Figure 12. 10 ml Picture
  • Figure 13. 25 ml Picture
  • Figure 14. Global Liposomal Doxorubicin Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Liposomal Doxorubicin Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Global Liposomal Doxorubicin Sales Volume by Type (2020 VS 2024 VS 2031) & (K Unit)
  • Figure 17. Global Liposomal Doxorubicin Sales Volume Market Share by Type, 2024 & 2031
  • Figure 18. Global Liposomal Doxorubicin Price by Type (2020-2031) & (USD/Unit)
  • Figure 19. Product Picture of Breast Cancer
  • Figure 20. Product Picture of Liver Cancer
  • Figure 21. Product Picture of Kidney Cancer
  • Figure 22. Product Picture of Multiple Myeloma
  • Figure 23. Product Picture of Ovarian Cancer
  • Figure 24. Product Picture of Other
  • Figure 25. Global Liposomal Doxorubicin Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 26. Global Liposomal Doxorubicin Sales Value Market Share by Application, 2024 & 2031
  • Figure 27. Global Liposomal Doxorubicin Sales Volume by Application (2020 VS 2024 VS 2031) & (K Unit)
  • Figure 28. Global Liposomal Doxorubicin Sales Volume Market Share by Application, 2024 & 2031
  • Figure 29. Global Liposomal Doxorubicin Price by Application (2020-2031) & (USD/Unit)
  • Figure 30. North America Liposomal Doxorubicin Sales Value (2020-2031) & (US$ Million)
  • Figure 31. North America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Europe Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Asia Pacific Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Asia Pacific Liposomal Doxorubicin Sales Value by Region (%), 2024 VS 2031
  • Figure 36. South America Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. South America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • Figure 38. Middle East & Africa Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Middle East & Africa Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
  • Figure 40. Key Countries/Regions Liposomal Doxorubicin Sales Value (%), (2020-2031)
  • Figure 41. Key Countries/Regions Liposomal Doxorubicin Sales Volume (%), (2020-2031)
  • Figure 42. United States Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. United States Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 44. United States Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Europe Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Europe Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Europe Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 48. China Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. China Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 50. China Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Japan Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. Japan Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 53. Japan Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 54. South Korea Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. South Korea Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 56. South Korea Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 57. Southeast Asia Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. Southeast Asia Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 59. Southeast Asia Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 60. India Liposomal Doxorubicin Sales Value, (2020-2031) & (US$ Million)
  • Figure 61. India Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • Figure 62. India Liposomal Doxorubicin Sales Value by Application (%), 2024 VS 2031
  • Figure 63. Liposomal Doxorubicin Industrial Chain
  • Figure 64. Liposomal Doxorubicin Manufacturing Cost Structure
  • Figure 65. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 66. Bottom-up and Top-down Approaches for This Report
  • Figure 67. Data Triangulation
  • Figure 68. Key Executives Interviewed